BRIEF-Alnylam Pharmaceuticals Q3 Adjusted EPS USD 3.01 Vs. IBES Estimate USD 0.42

Reuters
Oct 30
BRIEF-Alnylam Pharmaceuticals Q3 Adjusted EPS USD 3.01 Vs. IBES Estimate USD 0.42

Oct 30 (Reuters) - Alnylam Pharmaceuticals Q3 adjusted operating income USD 476.193 million.

  • Q3 net product revenue USD 1,249.026 million vs. IBES estimate USD 946 million
  • Q3 operating income USD 367.982 million
  • Q3 adjusted net income USD 396.18 million
  • Q3 net income USD 251.084 million

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10